Heparin infusion after successful percutaneous coronary intervention: A prospective, randomized trial

Acta Cardiologica

Volumn 64, Issue 1, 2009, Pages 65-70

  Zibaeenezhad, Mohammad Javad ^a   Mazloum, Yalda ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiography; Heparin infusion; PCI

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN;

ADULT; ANGINA PECTORIS; ARTICLE; BLEEDING; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; ELECTROCARDIOGRAM; EMERGENCY SURGERY; FEMALE; GROIN BLEEDING; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; CORONARY ANGIOGRAPHY; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE; TIME FACTORS;

EID: 61849103410     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.64.1.2034364     Document Type: Article

References (31)

1. Detre KM, Holmes DR Jr, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, Dorros GR, Bentivoglio LG, Kent KM, Myler RK. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990; 82: 739-50.
2. Simpfendorfer C, Belardi J, Bellamy G, Galan K, Franco I, Hollman J. Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987; 59: 267-9.
3. Niccoli G, Banning AP. Heparin dose during percutaneous coronary intervention: how low dare we go? Heart 2002; 88: 331-4.
4. Ferguson JJ, Dohmen P, Wilson JM, Vaughn WK, Khoshnevis R, Kmonicek P, McKinney AA, Plachetka JR. Results of a national survey on anticoagulation for PTCA. J Invas Cardiol 1995; 7: 136-41.
5. Friedman HZ, Cragg DR, Glazier SM, Gangadharan V, Marsalese DL, Schreiber TL, O'Neill WW. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994; 24: 1214-9.
6. Laskey MA, Deutsch E, Hirshfeld JW Jr, Kussmaul WG, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990; 65: 179-82.
7. Mabin TA, Holmes DR Jr, Smith HC, Vlietstra RE, Bove AA, Reeder GS, Chesebro JH, Bresnahan JF, Orszulak TA. Intracoronary thrombus: role of coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 5: 198-202.
8. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23: 1061-5.
9. Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996; 93: 667-71.
10. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
11. Van de Werf F. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions: latest results from the EPILOG and CAPTURE trials. Eur Heart J 1996; 17: 325-6.
12. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Intervention of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
13. Rabah M, Mason D, Muller DW, Hundley R, Kugelmass AD, Weiner B, Cannon L, O'Neill WW, Safian RD. Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. J Am Coll Cardiol 1999; 34: 461-7.
14. De Feyter PJ, Van den Brand M, Jaarman G, Van Domburg R, Serruys PW, Suryapranata H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation 1991; 83: 927-36.
15. Steffenino G, Meier B, Finci L, Velebit V, von Segesser L, Faidutti B, Rutishauser W. Acute complications of elective coronary angioplasty: a review of 500 consecutive procedures. Br Heart J 1988; 59: 151-8.
16. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006; 134: 3-19.
17. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-68.
18. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M. Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30.
19. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-6.
20. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP Jr. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-2.
21. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-9.
22. Bernardi V, Szarfer J, Summay G, Mendiz O, Sarmiento R, Alemparte MR, Gabay J, Berger PB. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). Am J Cardiol 2007; 99: 349-52.
23. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
24. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
25. Garachemani AR, Kaufmann U, Fleisch M, Meier B. Prolonged heparin after uncomplicated coronary interventions: A prospective, randomized trial. Am Heart J 1998; 136: 352-6.
26. More RS, Brack MJ, Gershlick AH. Heparin after angioplasty: an unresolved issue? Eur Heart J 1993; 14: 1543-7.
27. Neuhaus KL, Zeymer U. Prevention and management of thrombotic complications during coronary interventions: combination therapy with antithrombins, antiplatelets, and/or thrombolytics: risks and benefits. Eur Heart J 1995; 16: 63-7.
28. Gabliani G, Deligonul U, Kern MJ, Vandormael M. Acute coronary occlusion occurring after successful percutaneous transluminal coronary angioplasty: temporal relationship to discontinuation of anticoagulation. Am Heart J 1988; 116: 696-700.
29. Hollman J, Gruentzig AR, Douglas JS Jr, King SB III, Ischinger T, Meier B. Acute occlusion after percutaneous transluminal coronary angioplasty: a new approach. Circulation 1983; 68: 725-32.
30. Smith AJ, Holt RE, Fitzpatrick JB, Palacios IF, Gold HK, Werner W, Bovill EG, Fuster V, Jang IK. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J 1996; 131: 434-9.
31. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117: 777-82.